Table 3.
Slope, intercept, Pearson correlation coefficient, and predicted non-HDL-C values based on simple linear regression of non-HDL-C on apoB at baseline (ie, in drug-naïve patients) and endpoint (ie, last post-baseline on-treatment measurement)
| Na | Slope | Intercept | Pearson correlation coefficient (95% CI) | Predictedb non-HDL-C value (95% CI) given apoB of 0.8 g/L | Predictedb non-HDL-C value (95% CI) given apoB of 0.9 g/L | |
|---|---|---|---|---|---|---|
| Baseline (ie, in drug-naïve patients) | ||||||
| Pooled across treatment groups | 1,233 | 2.17 | 1.52 | 0.84 (0.82–0.86) | 3.25 (3.20–3.31) | 3.47 (3.42–3.52) |
| TG <2.26 mmol/L | 983 | 2.09 | 1.60 | 0.82 (0.80–0.84) | 3.27 (3.21–3.33) | 3.48 (3.43–3.53) |
| TG ≥2.26 mmol/L | 250 | 1.68 | 2.46 | 0.72 (0.65–0.77) | 3.80 (3.63–3.98) | 3.97 (3.81–4.13) |
| ERN/LRPT | 155 | 2.04 | 1.71 | 0.81 (0.74–0.86) | 3.34 (3.18–3.49) | 3.54 (3.40–3.68) |
| TG <2.26 mmol/L | 121 | 1.97 | 1.76 | 0.79 (0.71–0.85) | 3.34 (3.16–3.51) | 3.53 (3.39–3.68) |
| TG ≥2.26 mmol/L | 34 | 1.36 | 2.92 | 0.61 (0.34–0.78) | 4.01 (3.49–4.54) | 4.15 (3.69–4.61) |
| Pooled SIMVA | 561 | 2.20 | 1.48 | 0.84 (0.81–0.86) | 3.24 (3.16–3.32) | 3.46 (3.39–3.53) |
| TG <2.26 mmol/L | 444 | 2.14 | 1.51 | 0.84 (0.81–0.87) | 3.22 (3.14–3.31) | 3.44 (3.37–3.51) |
| TG ≥2.26 mmol/L | 117 | 1.53 | 2.75 | 0.67 (0.56–0.76) | 3.97 (3.70–4.24) | 4.12 (3.89–4.36) |
| Pooled ERN/LRPT + SIMVA | 517 | 2.18 | 1.51 | 0.85 (0.83–0.87) | 3.25 (3.17–3.33) | 3.46 (3.39–3.53) |
| TG <2.26 mmol/L | 418 | 2.04 | 1.67 | 0.81 (0.77–0.84) | 3.31 (3.21–3.40) | 3.51 (3.43–3.59) |
| TG ≥2.26 mmol/L | 99 | 1.99 | 1.91 | 0.80 (0.72–0.86) | 3.51 (3.24–3.77) | 3.70 (3.47–3.94) |
| Endpoint (ie, in drug-treated patients) | ||||||
| ERN/LRPT | 160 | 3.36 | −0.22 | 0.94 (0.92–0.96) | 2.48 (2.39–2.56) | 2.81 (2.74–2.88) |
| TG <2.26 mmol/L | 124 | 3.34 | −0.20 | 0.95 (0.92–0.96) | 2.47 (2.39–2.56) | 2.81 (2.74–2.88) |
| TG ≥2.26 mmol/L | 36 | 3.30 | −0.10 | 0.88 (0.78–0.94) | 2.54 (2.17–2.91) | 2.87 (2.55–3.18) |
| Pooled SIMVA | 564 | 3.35 | −0.34 | 0.95 (0.94–0.96) | 2.34 (2.31–2.38) | 2.68 (2.65–2.70) |
| TG <2.26 mmol/L | 447 | 3.36 | −0.35 | 0.95 (0.94–0.96) | 2.34 (2.31–2.37) | 2.67 (2.65–2.70) |
| TG ≥2.26 mmol/L | 117 | 3.29 | −0.25 | 0.92 (0.89–0.95) | 2.38 (2.26–2.50) | 2.71 (2.61–2.81) |
| Pooled ERN/LRPT + SIMVA | 519 | 2.78 | 0.15 | 0.85 (0.83–0.88) | 2.38 (2.33–2.42) | 2.65 (2.61–2.70) |
| TG <2.26 mmol/L | 419 | 2.61 | 0.26 | 0.82 (0.78–0.84) | 2.36 (2.30–2.41) | 2.62 (2.56–2.67) |
| TG ≥2.26 mmol/L | 100 | 3.25 | −0.21 | 0.97 (0.95–0.98) | 2.39 (2.32–2.46) | 2.72 (2.66–2.77) |
Notes:
a
Number of patients with paired apoB and non-HDL-C measurements
b
predicted non-HDL-C value (mmol/L) assuming apoB value of 0.8 or 0.9 g/L.
Abbreviations: apoB, apolipoprotein B; CI, confidence interval; ERN, extended-release niacin; HDL-C, high-density lipoprotein cholesterol; LRPT, laropiprant; SIMVA, simvastatin; TG, baseline triglyceride value.